Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company combining therapeutic development with a revenue-generating contract development and manufacturing organization (CDMO), reported financial results for the first half of 2026, highlighting growth in CDMO revenue and progress in its clinical manufacturing initiatives.
The company's first-half 2026 revenue reached $949,000, up from $773,000 in the prior-year period. Committed customer orders stood at approximately $3.1 million as of Aug. 16, 2026, including about $2.1 million already invoiced. These figures reflect the ongoing demand for Scinai's CDMO services, which are provided through its subsidiary, Scinai Biopharma Services Ltd., operating facilities in Jerusalem and Yavne, Israel.
A significant development is the advancement of an expanded clinical manufacturing and chemistry, manufacturing and controls (CMC) program for a U.S.-based biopharmaceutical company. Scinai has received approximately $650,000 in cash payments and advances for this program, with substantive activities already underway. A definitive agreement is still under negotiation, but the program is intended to support an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development. This initiative underscores Scinai's strategic focus on expanding its CDMO business and leveraging its manufacturing expertise to support advanced clinical programs.
The company continues to pursue approximately $5 million in CDMO revenue for the full year 2026, signaling confidence in its growth trajectory. Financially, Scinai reported an operating loss of approximately $4.6 million for the first half, compared with $3.8 million a year earlier. However, net income was approximately $1.6 million, a turnaround from a net loss of approximately $4.1 million in the prior-year period. This improvement was primarily driven by a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel. As of June 30, 2026, the company held cash, cash equivalents, and restricted cash totaling approximately $2.9 million.
Beyond its CDMO operations, Scinai continues to advance its therapeutic pipeline, including the PC111 and NanoAbs programs. These programs are part of the company's broader mission to develop innovative immunology therapies, with candidates licensed from the Max Planck Society and PinCell S.r.l. The company plans to host an investor webinar on Aug. 26, 2026, to discuss recent developments, financial performance, and upcoming milestones.
The announcement of these results and the progress in the U.S. clinical manufacturing program are important for investors and the biopharmaceutical industry, as they demonstrate Scinai's ability to generate revenue from its CDMO services while advancing its own therapeutic candidates. The expansion of the CDMO program with a U.S. partner could provide a steady revenue stream and validate the company's manufacturing capabilities. For more information, visit the company's newsroom at https://nnw.fm/SCNI.
